Northwire Canada EditionSaturday, October 17, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
Production / Operations

MedX Health reviews 2025

By The Northwire Desk — AI Analysis Dec 15, 2025 · 12:29 MDX · 0.055 MedX Health Corp
MDX · Price

Executive Summary

  • MedX Health Corp. released its 2025 Year-in-Review, highlighting over $2 million in investments toward technology platform development, intellectual property, and operational infrastructure to prepare for a large-scale commercial rollout in 2026.
  • The company appointed new executive leadership in Q3 2025, including a CEO, CTO, and COO, to consolidate technology development and strengthen commercial readiness.
  • Key operational milestones include the expansion of the DermSecure image database to ~85,000 clinically reviewed images, the launch of new photobiomodulation product lines (LumaVet and Oralase), and the release from an exclusive licensing agreement with Procter & Gamble, allowing direct commercial pursuit in beauty and aesthetics markets.

Key Details

  • Financial Investment: Over $2 million invested in fiscal 2025 in technology platform, IP portfolio, compliance, and operational infrastructure.
  • Executive Appointments:
    • Q3 2025: Appointed new Chief Executive Officer.
    • Q3 2025: Appointed first Chief Technology Officer (CTO), consolidating responsibility for technology development across specialist teams.
    • Q3 2025: Appointed Chief Operating Officer (COO).
  • DermSecure Platform & SIAscopy:
    • Proprietary image database expanded to approximately 85,000 clinically reviewed skin images.
    • Data includes detailed information on blood, melanin, and collagen to support AI-driven skin analysis and clinical decision-making.
    • SIAscopy IP remains the industry standard for longitudinal chromophore measurement and non-invasive skin analysis.
  • Commercial Agreements & Partnerships:
    • Health Partners Group: Executed commercial agreement in Q1 2025; phased commercial rollout to employer groups is proceeding as planned, expected to commence in Q1 2026.
    • Procter & Gamble (P&G): Released from prior exclusive licensing arrangement in Q1 2025, enabling MedX to directly pursue licensing and commercial opportunities in skin health, aesthetics, and beauty markets.
    • CRO Services: Provided technology and services to more than 26 Contract Research Organizations (CROs) across multiple jurisdictions in 2025.
  • Photobiomodulation (Cold Laser) Division:
    • Generated revenues during 2025, reflecting product line expansion and channel development.
    • Products hold FDA clearance and international regulatory approvals; operates within ISO 13485-certified quality system.
    • New Product Launches:
      • LumaVet: Veterinary-focused cold-laser system for pain management and tissue healing.
      • Oralase: Dental laser SKU targeting oral care and dental practice use; expected to be a meaningful growth contributor in 2026.
  • Strategic Outlook: Company views 2025 as a year of platform development and operational readiness, positioning for expanded commercial activities in 2026 subject to market conditions and regulatory considerations.

Notable Quotes

  • No direct quotes from the CEO or President were included in the provided text.
Read the original news release →

More from MedX Health Corp

Jun 25, 2026 · 23:52

MedX Health Launches SkinSecure SaaS to Target CRO Market, But Liquidity Crisis and Going Concern Risks Dominate

Other May 15, 2026 · 19:40

MedX Secures Runway with Debt Refinancing Amidst Dilution Concerns and Modest Cash Injection

Financings Mar 16, 2026 · 07:00

MedX Announces Application for Extension of Non-Brokered Private Placement

Financings Feb 27, 2026 · 11:44

MedX Health closes $2.7-million private placement

Financings Feb 27, 2026 · 07:00

MedX Announces $2,700,000 Initial Closing of Non-Brokered Private Placement of Series IV Convertible Loan Notes

Financings Feb 02, 2026 · 21:05

MedX Health arranges $5-million note financing

Financings